ArticleBMC infectious diseases2025
Association of overweight with treatment outcomes in pulmonary tuberculosis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors for treatment failure of drug-resistant pulmonary tuberculosis: results from a two-decade data analysis.Journal of thoracic disease · 2026Article
- Association between reduced kidney function and tuberculosis treatment outcomes.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundWhile overweight has been associated with a reduced risk of developing tuberculosis and diabetes with an increased risk, it remains unclear how these conditions influence anti-tuberculosis treatment outcomes. We aimed to examine the association of overweight with anti-tuberculosis treatment outcomes, and to evaluate whether this association differs by diabetes status, using two Korean cohorts.
methodsAmong patients with pulmonary tuberculosis enrolled in the multicenter prospective cohort study of pulmonary tuberculosis (COSMOTB) and the Korea Tuberculosis Cohort (KTBC) registry, we defined overweight as BMI ≥ 23 kg/m² according to national criteria and compared it with normal/underweight (BMI < 23 kg/m², per criteria). The primary and secondary outcomes were unfavorable outcomes and mortality. Multivariable regression analysis was conducted to evaluate the association of overweight with treatment outcomes, adjusting for potential confounders. Subgroup analyses were performed to assess the association in patients with and without diabetes.
resultsIn the COSMOTB dataset, the proportion of overweight individuals was 34.4%. Overweight was associated with a lower odds of unfavorable treatment outcome (adjusted odds ratio [aOR], 0.61; 95% confidence interval [CI], 0.37-0.97) and all-cause mortality during treatment (aOR, 0.49; 95% CI, 0.24-0.93). In subgroup analyses, these associations were observed in patients with diabetes but not in those without diabetes. In the KTBC database, overweight was also associated with reduced odds of unfavorable outcome in patients with diabetes.
conclusionIn this observational study, overweight was associated with improved treatment outcomes in pulmonary TB. This association was also significantly observed in patients with diabetes; however, causality cannot be inferred.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.